Key highlights:

  • 12-week open-label Phase 2b extension study commenced following positive interim analysis
  • Halneuron is a first-in-class, non-opioid NaV 1.7 selective analgesic for chemotherapy-induced neuropathic pain
  • Extension data will optimise dosing and support the end-of-Phase 2 FDA submission package
  • Top-line results from the double-blinded Phase 2b study expected autumn 2026
  • Phase 3 programme projected to start in the first half of 2027

Dogwood Therapeutics, Inc. (Nasdaq: DWTX) announced the commencement of a 12-week open-label Phase 2b extension study for Halneuron, its first-in-class non-opioid analgesic targeting chemotherapy-induced neuropathic pain. The extension follows a positive pre-planned interim analysis from the ongoing 4-week double-blinded Phase 2b study — a sequence of events that meaningfully de-risks the programme and accelerates the company's path toward a Phase 3 submission.

Chemotherapy-induced neuropathic pain is a debilitating and poorly managed complication affecting a substantial proportion of cancer patients undergoing treatment with neurotoxic agents including taxanes, platinum compounds and vinca alkaloids. The condition — characterised by burning, tingling, numbness and pain in the extremities — can persist long after chemotherapy ends, significantly impairing quality of life and in some cases leading patients to reduce or discontinue life-saving cancer treatment. Current management Options are inadequate, relying primarily on gabapentinoids, antidepressants and opioids, none of which was developed specifically for this indication and all of which carry significant tolerability burdens.

Halneuron's mechanism — selective inhibition of the NaV 1.7 sodium channel subtype — represents a scientifically rational approach to this problem. NaV 1.7 plays a specific role in pain signal transmission, and loss-of-function mutations in the channel are associated with congenital insensitivity to pain in humans — a compelling natural validation of the target. Dogwood Therapeutics' (NASDAQ: DWTX) selective approach aims to block pain without the broad neurological effects of earlier, less selective sodium channel blockers that failed due to cardiac and CNS toxicity.

The 12-week extension is strategically important for several reasons. Safety data over three months will be essential for an end-of-Phase 2 FDA submission and for designing a Phase 3 trial with appropriate duration. Dosing optimisation from the extension will allow the company to enter Phase 3 with greater confidence in its dose selection — one of the most common sources of Phase 3 failure in analgesic development. Top-line results from the double-blinded Phase 2b portion are expected in autumn 2026, with Phase 3 projected to begin in the first half of 2027.

For investors, the timeline is tight but credible. A positive double-blinded readout in autumn 2026 followed by an end-of-Phase 2 meeting with the FDA would put a Phase 3 start in early 2027 well within reach. The non-opioid positioning is commercially compelling in an environment where opioid prescribing faces increasing regulatory and social scrutiny, and where payers and regulators have explicitly signalled appetite for effective non-opioid pain therapies.